PMZ-1620 (sovateltide) along with standard treatment

DRUG2 trials

Sponsors

Pharmazz, Inc.

Conditions

Alzheimer DiseaseCerebral InfarctionCerebral IschemiaDementiaStroke, Acute

Phase 2

PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease

CompletedNCT04052737

Pharmazz, Inc.Alzheimer Disease, Dementia

Start: 2018-03-23End: 2023-01-06Updated: 2023-01-12

Phase 3

Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke

CompletedNCT04047563

Pharmazz, Inc.Cerebral Infarction, Cerebral Ischemia, Stroke, Acute

Start: 2019-11-10End: 2022-02-10Updated: 2023-10-18

Related Papers

Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial

Drugs2024-11-153 citations

Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke.

2021-01-1129 citations

Abstract WP161: Sovateltide Promotes Regeneration and Functional Recovery of Ischemic Brain by Improving Mitochondrial Function

Stroke2020-02-012 citations